Marc Funk, COO of Swiss-headquartered product development service specialist, Lonza, discusses the company’s remarkable recent fortunes, how it is implementing innovative efficiency improvements, and answers the question, “why Switzerland?”
We aspire to move the company and the relationship with our customers from being a functional service provider to the strategic partner of choice in supplying the most innovative medicines of the 2020s
Dr Thomas D. Madden, CEO and founder of Acuitas Therapeutics, shares the story behind their involvement in Pfizer and BioNTech’s COVID-19 vaccine, the numerous applications of the company’s proprietary lipid…
What were your main motivations to join Ipsen as chief business officer 16 months ago? I have worked in pharma for over 28 years across France, Portugal, Germany, Switzerland, and…
Cancer is one of the most frightening words in any language but is especially heart-wrenching when it comes to children. João de Bragança, President of Childhood Cancer International (CCI) and…
After 20 years, Novartis will no longer own one third of Roche’s shares after the two Swiss pharma giants agreed to a transaction worth USD 20.7 billion. While Roche touted…
This piece forms part of InFocus Biotechs to Watch Switzerland 2021, a deep dive into the Swiss biotech ecosystem and fundamentals, featuring data sets, feature articles, and profiles of some…
The Top Five countries in Europe for pharma production. All located in Western Europe, Switzerland punches well above its weight to take top spot. This data is taken from the 2021…
See our Cookie Privacy Policy Here